Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- AGYS +19.6%, EXP +6.5%, AS +2.9%, BILI +1.3%, CMBT +7.7%, ZBIO +5.7%, HSAI +1.2%
Other news:
- RLAY +10.6% (Announced promising Phase 2 zovegalisib data in vascular anomalies, showing 60% volumetric response and supportive safety profile)
- GILT +7.9% (Reached milestone with Boeing toward offering Sidewinder electronically steered antenna as future line-fit in-flight connectivity solution)
- INFU +3.9% (Authorizes a new $20 million stock repurchase program running from July 1, 2026 through June 30, 2028.)
- WVE +3.9% (Announces positive RestorAATion-2 trial update as WVE-006 achieved MZ-like phenotype with biweekly and monthly dosing)
- ECX +2.9% (Announced strategic framework agreement with May Mobility to develop and deliver autonomy-enabled vehicles and exclusive AV technology components.)
- TLX +2.7% (Completes patient enrollment for IPAX-2 study of TLX101-Tx in newly diagnosed glioblastoma; no dose-limiting toxicities observed.)
- MLYS +2.2% (Announced Phase 3 Launch-HTN lorundrostat data in hypertension and CKD will be presented orally at ESH 2026.)
- GDRX +2.0% (Integrated its discounts into TrumpRx.gov's expanded generic drug price transparency platform covering more than 600 medications.)
- CGEM +1.9% (Receives FDA orphan drug designation for CLN-049 in relapsed/refractory acute myeloid leukemia.)